Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2).
about
NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer ImmunotherapyPhase I clinical trial of the immunocytokine EMD 273063 in melanoma patients.A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology GroupThe development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma.Anti-GD2 Strategy in the Treatment of NeuroblastomaAntitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study.Differential internalization of hu14.18-IL2 immunocytokine by NK and tumor cell: impact on conjugation, cytotoxicity, and targeting.Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity.Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12.Phase II trial of hu14.18-IL2 for patients with metastatic melanoma.Intratumoral immunocytokine treatment results in enhanced antitumor effects.Radiofrequency ablation combined with KS-IL2 immunocytokine (EMD 273066) results in an enhanced antitumor effect against murine colon adenocarcinoma.Immune therapies for neuroblastoma.Current and Potential Uses of Immunocytokines as Cancer Immunotherapy.Anti-GD2 antibody therapy for GD2-expressing tumors.Immunocytokines: a review of molecules in clinical development for cancer therapy.Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy.Evolution of the magic bullet: Single chain antibody fragments for the targeted delivery of immunomodulatory proteins.Anti-GD2 immunotherapy for neuroblastoma.
P2860
Q26797345-FFF9A318-B9C3-47B1-9855-0F3111EB90BAQ33363235-C6B329E1-8CE4-42A9-8E61-6DA14391F8C7Q33370628-6A44332E-5174-434F-AE7C-6E02EB873C48Q34186886-AB46E149-A0DA-464E-86A5-636162D4183FQ34243887-5AFE8CBA-D134-41AA-88BB-F0B817D581EEQ34488726-1810CA55-1C9F-4891-9734-58E9EE268B66Q34683623-0DFE9788-21EC-402B-81DD-EEB0BC7A99D3Q35031732-F6AC64F2-D06D-4F9E-A543-349E1A0C4F01Q35556712-2A059FCB-E4D8-4B90-A134-39B929627067Q36412879-84805B10-BCEE-4CC9-B01D-EEAE603C3C3EQ36953492-D26506DA-CD61-499D-8F53-E67CB7DE0B03Q37328301-947C689E-0FE9-473F-B738-3F6A2EC9BDCAQ37431356-3A6D6D59-24D8-4733-815E-3B478F49BB36Q37637949-0D0DB713-3545-440A-92C0-220E868AE096Q37702283-96B3D7D2-B859-440E-A426-59FC3319E060Q38132742-6C1913D4-41BC-4FC0-A6CD-76A0038A2F16Q38916529-311A93B4-AF20-40B6-8C06-E2C1A2D0B597Q47277628-2C3E9498-EA77-4FF6-8B2F-0E40154DA771Q47554435-ECB7D4E9-0421-4742-955B-67626B799343
P2860
Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2).
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Activation of human effector c ...... fusion protein (ch14.18-IL2).
@en
type
label
Activation of human effector c ...... fusion protein (ch14.18-IL2).
@en
prefLabel
Activation of human effector c ...... fusion protein (ch14.18-IL2).
@en
P2093
P1476
Activation of human effector c ...... fusion protein (ch14.18-IL2).
@en
P2093
Gillies SD
Reisfeld RA
P304
P407
P577
1996-12-01T00:00:00Z